Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BrYet US
Princeton, New Jersey, United Statesbryet.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BrYet is a clinical-stage biopharmaceutical company focused on developing next-generation targeted therapies for cancer. The company utilizes its proprietary Targeted Delivery System (TDS) platform to enhance the efficacy and reduce the toxicity of established chemotherapeutic agents. Its lead candidate, BRY-801, is a folate-receptor-targeted formulation of paclitaxel currently being evaluated in Phase 1/2 clinical trials for advanced solid tumors, including ovarian and triple-negative breast cancers. BrYet aims to transform cancer treatment by delivering potent drugs directly to tumor cells while sparing healthy tissue.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeNanoparticleTargeted drug delivery therapy
- Industry
- Biotech
Beyond the preview
Go deeper on BrYet US.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BrYet US.